Immudicon
Cambridge
About Immudicon
Immudicon is a biotechnology company that creates complement-based biologics which targets and localizes immune cells to tumors. The platform modulates chemical barriers within the tumor microenvironment that create an immunosuppressive shield around the tumor. Immudicon was founded in 2011 and is based in Washington, D.C.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Funding stage: Seed
- Last round: Seed (Nov 2013)
- Website: immudicon.com
- Phone: +117033893339
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/immudicon-2457728 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.